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Abstract
Background Nivolumab with ipilimumab (the Regimen) is
the first immuno-oncology combination treatment to
demonstrate long-term clinical benefit for advanced mela-
noma patients. We evaluated the cost effectiveness of the
Regimen in this population, with and without the avail-
ability of overall survival (OS) data.
Methods A partitioned survival model and a Markov state-
transition model were developed to estimate the lifetime
costs and benefits of the Regimen versus ipilimumab.
These models were built with and without the availability
of OS data, as only progression-free survival data were
available from the head-to-head, phase III trial against
ipilimumab at the time of the National Institute for Health
and Care Excellence (NICE) submission. Patient utilities
and resource use data were sourced from trial data or the
literature.
Results Incremental cost-effectiveness ratios (ICERs) and
absolute costs were similar between the models with and
without OS data, but the model with OS data generated
more than 1 additional quality-adjusted life-year (QALY)
across both treatment arms. In both models, based on list
prices, the Regimen was the most cost-effective treatment.
Conclusions The analyses show that the Regimen is a cost-
effective treatment for advanced melanoma patients in
England, and methods to overcome the lack of OS can give
reasonable estimates of QALYs gained and ICERs.
Key Points for Decision Makers
Nivolumab plus ipilimumab is a cost-effective
treatment for advanced melanoma patients in
England
Assuming equal post-progression survival between
comparators of similar mechanism of action or using
data from earlier data-cuts can provide comparable
incremental cost-effectiveness ratios to those
calculated in the absence of overall survival data
1 Introduction
A key issue in modelling immunotherapies is that survival
data often suggest a plateau in overall survival (OS) but
clinical trials end or release data-cuts before this has been
fully demonstrated, causing uncertainty in cost-effective-
ness analyses [1]. This issue has become more prevalent as
timelines for regulatory and reimbursement submissions
become accelerated, with companies seeking approval
based on fewer, less mature survival data.
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Ipilimumab and nivolumab are fully human, monoclonal
immunoglobulin antibodies (IgG1k and IgG4 HuMab,
respectively) that act as checkpoint inhibitors of cytotoxic
T lymphocyte antigen-4 (CTLA-4) and programmed death-
1 (PD-1) at their distinct, yet complementary, positions
within the T cell response pathway. Ipilimumab stops the
immune response from being ‘switched off’, allowing the
production of active T cells to continue and potentially
increasing the number of activated T cells surrounding the
tumour [2]. Nivolumab stops the inactivation of T cells at
the tumour site, allowing more active T cells to infiltrate
and destroy the tumour [3].
Used together, nivolumab plus ipilimumab, or the
Regimen, potentiates immune-mediated tumour destruc-
tion, stimulating the patient’s immune system to attack
cancer cells and destroy the tumour through intrinsic pro-
cesses. A challenge in assessing immunotherapy benefit is
that patients may experience an increase in tumour size
before a response is seen, known as pseudo-progression
[4].
A phase I trial showed an unprecedented 68% OS at
3 years in unresectable melanoma patients treated with the
Regimen [5]. The primary source of information for the
effectiveness of the Regimen and ipilimumab monotherapy
is the CheckMate 067 study, an international, randomised
controlled trial (RCT) that demonstrated superior OS and
progression-free survival (PFS) for the Regimen compared
with ipilimumab. Latest CheckMate 067 data show 3-year
OS rates of 57% for the Regimen versus 31% for ipili-
mumab monotherapy [6].
The Regimen is associated with a predictable safety
profile, with immune-related adverse events (AEs) that are
acute and generally reversible and in line with well-
established safety algorithms in the majority of patients.
Recent evidence shows that many patients who discontin-
ued due to AEs have better response rates and PFS than
those who did not, with the presence of AEs potentially
indicating a good physiological response to the treatment
[7].
The Regimen was assessed for the treatment of adults
with advanced (unresectable or metastatic) melanoma by
the National Institute for Health and Care Excellence
(NICE) in June 2016. At the time of the manufacturer’s
submission to NICE (January 2016), OS data were not
available; therefore, a common post-progression treatment
effect was assumed for all immunotherapies compared. The
relevant standard of care was ipilimumab, BRAF inhibitor
(dabrafenib or vemurafenib) monotherapy or pem-
brolizumab (approved in August 2015), which was added
as a comparator due to its availability and subsequent
increased use during the appraisal process [8, 9]. Nivolu-
mab monotherapy was available for use subsequently, and
was not a comparator for the Regimen. These treatments
demonstrated significant clinical benefit over traditional
chemotherapy but, unfortunately, continue to have limita-
tions such that many patients did not achieve durable
response and long-term survival. Ipilimumab, BRAF inhi-
bitors and pembrolizumab were included in the model for
the NICE appraisal of the Regimen [9], but for the purposes
of this article, only the comparison to ipilimumab is shown.
The analysis presented here compares the cost effec-
tiveness of the Regimen with ipilimumab, in the Check-
Mate 067 trial population in England, using two different
models: one model each with 18-month (OS unavailable)
and 36-month (OS available) CheckMate 067 data-cuts
(Fig. 1).
2 Method
2.1 Model Structure
A partitioned survival model and a Markov state-transition
model were developed in Microsoft Excel (Microsoft
Corp., Redmond, WA, USA) to estimate the lifetime costs
and benefits of the Regimen versus ipilimumab, from the
UK healthcare system perspective.
Both models were based on a three-health state struc-
ture, similar to previous models submitted to health tech-
nology assessment agencies for ipilimumab and nivolumab
monotherapy [10], and both used the most recent efficacy
and safety data available at the time of building.
Health states were defined by three different measures
(Fig. 2):
Fig. 1 Available clinical trial data. 18-month overall survival data
were not available at the time of modelling for the National Institute
for Health and Care Excellence submission. Ipi ipilimumab, KM
Kaplan–Meier, OS overall survival, PFS progression-free survival
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• Progression status for modelling survival and quality of
life (three states): progression-free, progressed and
dead.
• Time since treatment initiation and time to death for
modelling resource use (six states): first, second, third
and fourth year after treatment initiation, fifth and
subsequent years after treatment initiation, 12 weeks
before death (palliative care) and death.
• Treatment status for modelling drug cost and AEs (two
states): on treatment and off treatment.
The two models varied in their basic structure. With
CheckMate 067 OS data, an area under the curve (AUC)
approach (partitioned survival) could be used, but without
the OS data, a state-transition model was used. Thus, rather
than the average simulated patient having their survival
dependent on time and fitted survival curves, each patient
has a probability of moving from one state to another, and
it is the proportion of patients in each of these states that
determines OS and PFS. Although these two modelling
approaches require different assumptions, research has
shown that they should be functionally equivalent [11].
Data for the comparative effectiveness of the Regimen
and ipilimumab were taken from the CheckMate 067 and
MDX010-20 (phase III RCT of ipilimumab versus gp100
vaccine) clinical trials. Trial data were used for utilities and
safety; resource use estimates were obtained from the lit-
erature and a validation meeting with UK clinicians.
Clinicians were selected as experts in the treatment of
advanced melanoma who had experience of immunother-
apies from clinical studies and real-world use, with con-
sensus reached through advisory board discussion and
questioning.
2.2 Modelling Survival for the Regimen
and Ipilimumab Without CheckMate 067
Overall Survival (OS) Data
At the time of submission to NICE, when OS data were not
available, CheckMate 067 trial data were used to estimate
pre-progression survival (PrePS) and time to progression
(TTP). PFS was estimated from TTP and PrePS, up to the
longest follow-up available at the time from Check-
Mate 067 (1.5 years).
In the absence of head-to-head OS data, patient-level
data from MDX010-20 and CheckMate 066 (for ipili-
mumab and nivolumab monotherapy, respectively) were
used to estimate post-progression survival (PPS) for all
immunotherapies.
Transition probabilities were derived from these curves
and used to estimate the proportion of patients in the pro-
gression-free, progressed and dead states over time.
For the Regimen and ipilimumab, patient-level trial data
were used to fit parametric curves adjusted for the
covariates selected based upon the Korn meta-analysis,
which analysed factors affecting prognosis within
advanced melanoma treated with palliative chemotherapy
[12]. This list was validated at the UK clinician advisory
board:
• Treatment (only included for TTP and PrePS)
• Trial (MDX010-20 or CheckMate 066, only included
for PPS)
• Baseline Eastern Cooperative Oncology Group score
• Lactate dehydrogenase
• Metastasis stage
• History of brain metastases
• Age group
• Sex
• Subsequent ipilimumab (only included for PPS).
2.2.1 Time to Progression
Due to the trial protocol effect where the first tumour
assessments were performed at Week 12 in Check-
Mate 067, Kaplan–Meier (KM) data were used for the first
84 days of TTP. This cut-off date was chosen based on
inspection of the KM curve and timing of patients’ first
clinic visits within the included clinical trial.
In accordance with NICE guidance [considering the
visual fit of the parametric curves compared to the KM
curves, clinical plausibility of extrapolation, and compar-
ison of the Akaike information criteria (AIC) and Bayesian
information criteria (BIC)], the log-normal curve was
chosen out of the six parametric curves fitted to TTP [13]
and used for extrapolation for the entire model time
horizon.
Fig. 2 Model structure
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2.2.2 Pre-Progression Survival
For PrePS, none of the six curves provided a good visual fit
to the data. Therefore, the KM data were used directly to
model PrePS, up to the latest follow-up (1.5 years). It was
assumed that between 1.5 and 3 years, if a patient had not
progressed, their survival was equivalent to that of the
general population. This is because in the data-cut with
longest follow-up of 1.5 years, no deaths were observed on
the Regimen arm after 271 days or on the ipilimumab arm
after 342 days.
2.2.3 Post-Progression Survival
A log-logistic curve was chosen for the base-case PPS
curve, based on the NICE Decision Support Unit guidance
[13]. It was conservatively assumed that PPS is the same
for all immunotherapies, including ipilimumab and the
Regimen, after controlling for patient characteristics.
2.2.4 OS
OS between Year 1.5 and Year 3 was based on PrePS (as in
Sect. 2.2.2) and PPS from MDX010-20 and Check-
Mate 066. From Year 3 onwards, long-term OS for the
Regimen and ipilimumab was based on pooled ipilimumab
data from Schadendorf et al. [14]. The pooled analysis
showed a plateau in the OS curve beginning around Year 3
and continuing to the end of the 10-year follow-up [14].
This was also assumed to be applicable to long-term OS for
the Regimen due to the similarity of the mechanism of
action. The Gompertz curve was selected for the base case,
following NICE guidance [13]. Life tables for England
were used as a minimum threshold for cycle mortality in
the model [15].
2.3 Modelling Survival for the Regimen
and Ipilimumab with CheckMate 067 OS Data
When OS data became available, patient-level data from
CheckMate 067 were used to fit parametric curves for PFS
(from a 36-month data-cut) and OS for the Regimen and
ipilimumab. Due to the protocol effect mentioned previ-
ously, KM data were used for the PFS curves before
91 days, chosen based on inspection of the KM curve and
timing of patients’ first clinic visit in the trial. Originally
84 days, the updated data-cut showed more events between
84 and 91 days, which made 91 days the more appropriate
cut-off. After 91 days, Gompertz curves were used to fit
PFS data; dependent curves (treatment used as a covariate)
were fitted due to the assumption of proportional hazards
holding under the log-cumulative hazard plots and pro-
portional hazards test. Considering the visual fit of the
parametric curves compared to the KM curves, clinical
plausibility of extrapolation, and comparison of the AIC
and BIC, a Gompertz fit was used for the Regimen OS data
and a log-normal curve for the ipilimumab OS data;
independently modelled curves were fitted for each treat-
ment as the proportional hazards assumption did not hold.
These curves were used for the first 2 years, and data from
the Schadendorf et al. [14] paper were used in the long-
term (using a Gompertz curve fit as per the model without
OS data). Transition probabilities were derived from these
curves and used to estimate the proportion of patients in the
progression-free, progressed and dead states over time.
KM data and fitted curves for PFS are presented in
Figs. 3 and 5, and those for OS are presented in Figs. 4 and
6. Curve parameters are detailed with key model inputs in
Table 1. The differences between the curves of the models
with and without OS data are due to the different curve fits,
methodologies and data-cuts taken from CheckMate 067.
2.4 Time on Treatment
For both models, time on treatment was taken from patient-
level data from CheckMate 067, and a log-logistic curve
was used for extrapolation, selected as per NICE guidance
using the process detailed previously.
A maximum treatment duration of 2 years was assumed
in the models for nivolumab. Clinical consensus from UK
clinicians is that stopping nivolumab monotherapy treat-
ment at 2 years is an acceptable recommendation for the
small minority of patients who may still be receiving
treatment at this time. This treatment continuation rule was
tested in a range of scenario analyses, including the per-
centage of ‘on treatment’ patients discontinuing treatment
Fig. 3 Short-term progression-free survival curve fits and Kaplan–
Meier curves with and without CheckMate 067 overall survival.
36-month data-cut used for the Regimen and ipilimumab. Ipi
ipilimumab, KM Kaplan–Meier, OS overall survival, w/OS model
with CheckMate 067 overall survival data, w/o OS model without
CheckMate 067 overall survival data
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at 2 years, and the maximum treatment duration [Elec-
tronic Supplementary Material (ESM) Table S1].
As data from the CheckMate 067 trial indicate no loss of
response upon early discontinuation of therapy for many
patients [7], it is assumed that treatment effect is main-
tained when patients discontinue PD-1 inhibitors. In
CheckMate 067, only 24.3% of patients were still on
nivolumab within the Regimen arm at 18 months, and of
those that discontinued due to AEs, 76.2% of patients
continued to exhibit response to the Regimen [16].
Ipilimumab patients receive four doses, as specified in
the licensed indication, with 100, 95, 85 and 70% of
patients receiving Dose 1, 2, 3 and 4, respectively (taken
from CheckMate 067).
Drug costs were calculated using the method of
moments [17]. Assuming a log-normal distribution for
body weight, the proportion of patients requiring each
possible number of vials was calculated based on the dis-
tribution derived from the individual patient weights. This
is an accurate method of accounting for wastage, assuming
that no vial sharing occurs.
For nivolumab, vial sizes of 40 and 100 mL are avail-
able, resulting in 10% vial wastage. However, only a vial
size of 50 mL was available for pembrolizumab, resulting
in 16% vial wastage.
2.5 Health-Related Quality of Life
EQ-5D-3L data collected in CheckMate 067 were used in
the base case, with utilities calculated using the UK tariff.
Utilities were estimated treatment-dependently for the
progression-free and treatment-independently for pro-
gressed health-states, as AE disutilities were not captured
elsewhere.
The key element we aimed to characterise is how pro-
gression status impacted utility over time, controlling for
baseline utility and treatment, as this is one of the key
drivers of the economic model. Progression status was
defined using a simple time-varying indicator of progres-
sion and a more granular definition, taking into account
response status at 6 months combined with the time-vary-
ing indicator.
Results showed that including the combined response
status/progression status variables (in place of a simpler
post-progression variable) did not help further distinguish
the model. There was also a large reduction in the available
number of visits/patients for that analysis due to censoring
patients with non-evaluable response status at 6 months.
The final model selected includes progression status,
baseline utility value and treatment arm; age and sex were
Fig. 4 Short-term overall survival curve fits with and without
CheckMate 067 overall survival. 36-month data-cut used for the
Regimen and ipilimumab. Ipi ipilimumab, KM Kaplan–Meier, OS
overall survival, w/OS model with CheckMate 067 overall survival
data, w/o OS model without CheckMate 067 overall survival data
Fig. 6 Long-term overall survival curves with and without Check-
Mate 067 overall survival. Ipi ipilimumab, OS overall survival, w/OS
model with CheckMate 067 overall survival data, w/o OS model
without CheckMate 067 overall survival data
Fig. 5 Long-term progression-free survival curves with and without
CheckMate 067 overall survival. Ipi ipilimumab, OS overall survival,
w/OS model with CheckMate 067 overall survival data, w/o OS
model without CheckMate 067 overall survival data
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Table 1 Summary of key inputs
Parameter Base-case
value
Distribution Source
Model settings
Discount rate—costs and QALYs 0.035 Fixed NICE guide to the methods of technology
appraisal [23]
Drug dosing and costs
Drug cost of nivolumab (after first 4 cycles) per
administration
£2730.74 Fixed MIMS [24]
Drug cost of nivolumab (first 4 cycles) per
administration
£1003.78 Fixed
Drug cost of ipilimumab per administration £19,785.97 Fixed MIMS [24]
AEs (costs and utility decrements)
Total AE costs for nivolumab ? ipilimumab £1628.42 Normal (SE = 325.68) CheckMate 067 [16], NHS reference costs
[18]Total AE costs for ipilimumab £928.56 Normal (SE = 185.71)
Annual AE utility decrement for
nivolumab ? ipilimumab
- 0.03 Beta (a = 24.16,
b = 692.02)
CheckMate 067 [16]
Annual AE utility decrement for ipilimumab - 0.03 Beta (a = 24.22,
b = 747.98)
Resource use and costs
Treatment initiation—one-off £740.77 Normal (SE = 148.15) PSSRU [19], NHS reference costs [18]
Pre-palliative care period—year 1 (per week) £96.80 Normal (SE = 19.36) PSSRU [19], NHS reference costs [18]
Pre-palliative care period—year 2 (per week) £48.40 Normal (SE = 9.68) PSSRU [19], NHS reference costs [18]
Pre-palliative care period—year 3 (per week) £29.04 Normal (SE = 5.81) PSSRU [19], NHS reference costs [18]
Pre-palliative care period—year 4 (per week) £29.04 Normal (SE = 5.81) PSSRU [19], NHS reference costs [18]
Pre-palliative care period—year 5 and beyond (per
week)
£29.04 Normal (SE = 5.81) PSSRU [19], NHS reference costs [18]
Palliative care period (per week) £217.16 Normal (SE = 43.43) Oxford Outcomes [25], PSSRU [19], NHS
reference costs [18]
End-of-life care—one-off £1463.89 Normal (SE = 292.78) King’s Fund [26], PSSRU [19], NHS
reference costs [18]
Length of palliative care period (weeks) 12.00 Fixed Clinical opinion
Utilities Multivariate normala (see
ESM Table S3)
CheckMate 067 [16]
Utilities coefficient—intercept 0.4259
Utilities coefficient—post-progression – 0.0329
Utilities coefficient—baseline EQ-5D 0.4765
Utilities coefficient—treatment ipilimumab – 0.0314
Utilities coefficient—treatment
nivolumab ? ipilimumab
– 0.0337
Pre-progression ? days left\ 30 days 0.7954 Calculated from utilities
coefficients
CheckMate 067 [16]
Pre-progression ? days left C 30 days 0.7954
Post-progression ? days left\ 30 days 0.7625
Post-progression ? days left C 30 days 0.7625
Modelling survival for the Regimen and ipilimumab without CheckMate 067 OS data
Treatment duration Multivariate normala (see
ESM Table S4)
CheckMate 067 [16]
Nivolumab BRAF – ve (log-logistic)
TOT nivolumab BRAF—scale 4.7789
TOT nivolumab BRAF—Ln shape 0.2165
Nivolumab BRAF ? ve (log-logistic)
TOT nivolumab—scale 4.4742
TOT nivolumab—Ln shape 0.2165
48 D. Lee et al.
Table 1 continued
Parameter Base-case
value
Distribution Source
Efficacy parameters Multivariate normala (see
ESM Table S5)
CheckMate 067 [16]
TTP post-84 days BRAF – ve (log-normal)
TTP post-84 days—intercept 4.5009
TTP post-84 days—Regimen 2.1103
TTP post-84 days—Ln sigma 0.9728
TTP post-84 days BRAF ? ve (log-normal)
TTP post-84 days—intercept 4.0600
TTP post-84 days—Regimen 2.1103
TTP post-84 days—Ln sigma 0.9728
PPS BRAF – ve (log-logistic) Multivariate normala (see
ESM Table S6)
MDX010-20 [10], CheckMate 066 [27]
PPS—scale 5.5996
PPS—Regimen 0.0000
PPS—Ln shape – 0.3353
PPS BRAF ? ve (log-logistic)
PPS—scale 5.4835
PPS—Regimen 0.0000
PPS—Ln shape – 0.3353
Pooled ipilimumab long-term OS (rebase at year
3) (Gompertz)
Multivariate normala (see
ESM Table S7)
Schadendorf et al. [14]
Pooled ipilimumab long-term OS—shape – 0.0020
Pooled ipilimumab long-term OS—rate – 7.6209
Modelling survival for the Regimen and ipilimumab with CheckMate 067 OS data
Treatment duration
Nivolumab (log-logistic) Multivariate normala (see
ESM Table S8)
CheckMate 067 [16]
TOT nivolumab within the Regimen—parameter
1
– 0.1085
TOT nivolumab within the Regimen—parameter
2
4.8152
TOT nivolumab within the Regimen—parameter
3
0.0000
Efficacy parameters
PFS post-91 days Multivariate normala (see
ESM Table S9)
CheckMate 067 [16]
PFS post-91 days—parameter 1 – 0.0035
PFS post-91 days—parameter 2 – 5.1984
PFS post-91 days—parameter 3 – 0.9906
OS Multivariate normala (see
ESM Table S10)
CheckMate 067 [16]
OS—parameter 1 6.4216
OS—parameter 2 0.2821
OS—parameter 3 0.0000
Pooled ipilimumab long-term OS Multivariate normala (see
ESM Table S11)
Schadendorf et al. [14]
Pooled ipilimumab long-term OS—parameter 1 – 0.0431
Pooled ipilimumab long-term OS—parameter 2 – 2.5571
Pooled ipilimumab long-term OS—parameter 3 0.0000
AE adverse event, ESM electronic supplementary material, MIMS Monthly Index of Medical Specialities, NHS National Health Service, NICE
National Institute for Health and Care Excellence, OS overall survival, PFS progression-free survival, PPS post-progression survival, PSSRU
Personal Social Services Research Unit, QALY quality-adjusted life-year, SE standard error, TOT time on treatment, TTP time to progression, –ve
negative, ?ve positive
aVariance covariance matrices are described, which are used to inform multivariate distributions for sampling inputs for probabilistic sensitivity
analysis
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not significant in the statistical models. In this final model,
all parameters included are significant.
The treatment arms for the Regimen and ipilimumab
had utility decrements calculated from the statistical model
fitted from the CheckMate 067 data.
2.6 Resource Use and Drug Costs
The frequency of drug administration was taken from
CheckMate 067 for ipilimumab (3 mg/kg every 3 weeks
for 12 weeks) and nivolumab (1 mg/kg every 3 weeks for
the first 12 weeks, then 3 mg/kg every 2 weeks) [2, 3].
Health-state costs were split by time on treatment: Year 1,
2, 3, 4, 5 ? and palliative care period in the last 12 weeks
from death. These costs included outpatient, inpatient,
terminal care, home care, laboratory tests, radiological
examinations and pain control costs. Standard UK cost
sources were used to cost AEs, resource use and adminis-
tration costs. The cost year used was 2015, and the latest
available costs from the UK National Health Service
(NHS) reference costs and Personal Social Services
Research Unit (PSSRU) were used [18, 19].
The proportion of patients on each subsequent treatment
was taken from CheckMate 067.
2.7 Adverse Events
Drug-related AEs were captured within the model and
classified as either any-grade endocrine disorder, Grade 2
or higher diarrhoea, or Grade 3 or higher other drug-related
AEs, based on clinical expert opinion as to which AEs are
likely to have a large impact on outcomes. There was no
restriction on the minimum percentage of patients experi-
encing an AE, and patient-level AE data from Check-
Mate 067 were used for the Regimen and ipilimumab arms.
CheckMate 067 trial data used in AE calculations included
the proportion of patients experiencing AEs and the num-
ber of hospitalisation days. Total AE costs are provided in
Table 1. These are applied as a total one-off cost at the start
of the model.
2.8 Sensitivity Analysis
Deterministic and probabilistic sensitivity analysis were
included in the model. One-way sensitivity analysis
involved calculating the model result after varying each
parameter individually to its lower and upper bounds, and
probabilistic sensitivity analysis involved running the
model 1000 times, each time taking a random value for all
parameters across a defined distribution. The distributions
used in the model for these analyses are included in
Table 1.
Scenario analysis were also performed, testing the
assumptions around specific parameters such as survival
distributions and dosing calculations.
3 Results
At list price, both models produced an incremental cost-
effectiveness ratio (ICER) of approximately £4500 for the
Regimen versus ipilimumab monotherapy (Table 2).
Life-years (LYs) and quality-adjusted life-years
(QALYs) gained were greater in the model with Check-
Mate 067 OS data than in the model without OS data
(Table 2). This was because the longer PFS and OS follow-
up data showed that both the Regimen and ipilimumab had
greater effectiveness than that predicted in the model using
the earlier data-cut without CheckMate 067 OS data (the
first signs of plateau can be seen within the longer data-
cut). Although the QALYs and LYs were greater in the
model with OS data, the difference (increment) between
them was still comparable to the first model.
Overall costs for each treatment between models were
very similar. Subsequent treatment costs were slightly
Table 2 Base-case incremental cost-effectiveness results
Treatment arm 2 years Total 2 years
incremental
Total incremental Cost per QALY (£)
QALYs LYs Costs (£) QALYs LYs QALYs LYs Costs (£) QALYs LYs
Base case full incremental cost-effectiveness results (list price) without CheckMate 067 OS
Ipilimumab 0.91 1.17 118,474 2.80 3.64
Nivolumab plus ipilimumab 1.09 1.41 129,912 5.34 6.83 0.18 0.24 11,438 2.54 3.19 4502
Base case full incremental cost-effectiveness results (list price) with CheckMate 067 OS
Ipilimumab 1.03 1.33 119,594 3.88 5.02
Nivolumab plus ipilimumab 1.17 1.52 131,678 6.74 8.55 0.14 0.18 12,084 2.86 3.53 4225
LY life-year, OS overall survival, QALY quality-adjusted life-year
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higher in the model without OS as more patients were
moving into the progressed state.
One-way sensitivity analysis showed that the key drivers
of both models were the parameters used to inform the OS
curves (ESM Figures S1 and S2).
Probabilistic sensitivity analysis results were consistent
with deterministic results, showing that the results were
robust to the modelled uncertainty (ESM Figures S3 and
S4). Conducting probabilistic sensitivity analysis for only
the parameters relating to OS demonstrated that these
parameters contributed 96.3% of the overall parameter
uncertainty of the net monetary benefit in the model with
CheckMate 067 OS [20]. For the model without Check-
Mate 067 OS, OS inputs (parameters for PPS curves and
for long-term OS curves) contributed 53.7% of the overall
uncertainty around the net monetary benefit. In this model,
the uncertainty contributed by survival parameters is much
less because there were no changes in the difference
between OS post-progression due to assuming equal PPS.
Cost-effectiveness acceptability curves showed the
Regimen to be the most likely to be cost effective at
willingness-to-pay thresholds of £30,000 and £50,000
(ESM Figures S5 and S6).
Scenario analysis showed that the results were robust to
changes in the treatment continuation rule, with all sce-
narios showing cost effectiveness for the Regimen versus
ipilimumab in the model with CheckMate 067 OS data.
Only in the absence of the treatment continuation rule (i.e.
patients could continue treatment for up to 40 years) was
the Regimen not cost effective versus ipilimumab in the
model without CheckMate 067 OS at a £30,000 willing-
ness-to-pay threshold (although cost effectiveness was
observed at a £50,000 threshold). For all other scenarios,
including model fits, time horizon and utilities, the Regi-
men remained cost effective across both models (ESM
Tables S1 and S2).
4 Discussion
Our work shows that, in this case, assuming equal PPS
across immunotherapies provides a relatively accurate
estimate for ICER calculations in the absence of OS data
(net benefit assuming a willingness-to-pay threshold of
£30,000 was within 12% of the model with OS data),
although absolute estimates were far from the clinical trial
projections.
From our analyses, using two different modelling
methods, we have identified that the Regimen is cost
effective versus ipilimumab in the UK. The cost-effec-
tiveness argument is driven by increased OS compared
with current care, with relatively short treatment duration,
and a reduction in the requirement for subsequent
treatment. Using the same models described earlier, the
Regimen was also shown to be cost effective against ipil-
imumab, pembrolizumab and BRAF inhibitors as part of
technology appraisals to NICE and the Scottish Medicines
Consortium, leading to reimbursement in their corre-
sponding healthcare systems [9, 21].
When OS data were unavailable, we made the
assumption of equal PPS as the different treatments work
by activating the immune system. However, this does have
its limitations as the treatments will not have identical
mechanisms of action or treatment effects. This may
indicate that this technique should only be used when all
treatments have reasonably similar mechanisms of action.
Other possibilities to address the lack of mature data would
include response-based modelling, using a patient’s
response status to predict their subsequent survival and
resource use [22].
The mechanism behind immunotherapies is now well-
understood, but the long-term effects are still being
investigated. When modelling long-term survival, using
historic data from the same disease area to establish sur-
rogate relationships is a well-established technique, but this
is difficult with immune-oncology therapies due to a lack
of data. Being able to model long-term survival with the
Schadendorf et al. [14] data allowed us to replicate the
expected long-term survival of the Regimen; as ipilimumab
is part of the therapy, assuming a similar survival long-
term profile to ipilimumab patients is a reasonable
assumption. Consequently, this model reflected the
expectation that a substantial number of patients will
achieve considerable long-term survival. For models in
other disease areas, if no OS data are available but historic
data are, assuming equal PPS for a treatment with a similar
mechanism of action is a viable option. In this study, we
assumed that the transition from progressed to death was
equal for both arms (data from MDX010-20 and Check-
Mate 066) and informed long-term OS for each arm using
the same data source (Schadendorf et al. [14]). However,
when comparators have different mechanisms of action,
and no supporting long-term data, estimating long-term
survival and cost effectiveness would be considerably more
challenging.
The key model assumptions and structures have been
validated by clinical and health economics experts, and
model results accurately reflect those seen in the literature
and in clinical trials over the last 18 months (Table 3).
Longer-term model results are slightly different, with the
Regimen model with OS data results underestimating
3-year OS compared with that seen in the literature (57 and
68%, respectively) [5]. For ipilimumab, the model result
over-estimates OS when compared with the Schadendorf
et al. [14] data. This difference may be due to a greater
benefit seen in the short-term in the CheckMate 067 data
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than in the Schadendorf et al. [14] data (because of the
greater availability of effective subsequent treatments), but
the long-term benefit from the Schadendorf et al. [14] data
is still applied to the model arm after 2 years.
In our case study, we found that assuming equal PPS
underestimated total LYs and QALYs but provided rea-
sonable estimates of total costs, incremental costs, LYs and
QALYs. Although we cannot determine whether the dif-
ferences in model results are due to different modelling
approaches or the different data used in each model, we
observe that most of the efficacy results from the model
with OS more closely match the trial results (Table 3).
There is little difference in costs between the two models,
which may be down to the majority of costs being accrued
in the first 2 years, where there is more overlap in the data
used in the models.
Modelling the cost effectiveness of treatments presents
considerable challenges and limitations. The extended
duration of benefit provided by immunotherapies leads to
uncertainty in appropriate treatment duration; this greatly
influences the overall cost. Often, treatments show a large
benefit for PFS but lack mature OS data. This lack of OS
data is set to increasingly become an issue in reimburse-
ment, with immunotherapies providing a step-change in the
treatment and survival of melanoma (and in other diseases),
with an uncertain duration of benefit. These challenges are
also likely to become apparent when valuing the benefit of
newer gene therapies. Although it may lead to conservative
estimates of OS, our analysis shows that for comparators
with similar mechanisms of action, assuming equal PPS or
using data from earlier data-cuts can go some way to
overcoming this limitation, providing comparable ICERs in
the absence of OS data.
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Table 3 Model validation with clinical trial results
Model without CheckMate 067 OS
(%)
Model with CheckMate 067 OS
(%)
Trial result
(%)
Source
PFS
Ipilimumab 6 months 24.6 31.7 24.8 CheckMate 067 [16]
Ipilimumab
12 months
15.6 18.3 18.0 CheckMate 067 [16]
Ipilimumab
18 months
12.4 13.6 13.0 CheckMate 067 [16]
Regimen 6 months 55.3 62.9 62.0 CheckMate 067 [16]
Regimen 12 months 45.7 51.2 49.0 CheckMate 067 [16]
Regimen 18 months 41.5 45.7 46.0 CheckMate 067 [16]
OS
Ipilimumab 1 year 55.1 65.6 66.7 CheckMate 067 [6]
Ipilimumab 2 years 31.2 45.1 44.9 CheckMate 067 [6]
Ipilimumab 3 years 21.2 34.8 21.0 Schadendorf et al.
[14]
Regimen 1 year 69.9 76.1 73.2 CheckMate 067 [6]
Regimen 2 years 49.7 63.9 64.1 CheckMate 067 [6]
Regimen 5 years 35.0 51.2 47.3 CheckMate 004 [5]
OS overall survival, PFS progression-free survival
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Data Availability Statement The economic models used in this
study are not publicly available in order to protect the commercial in
confidence discounts that are in place for both nivolumab and
ipilimumab.
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